Katri Korpela1, Annika Mutanen2, Anne Salonen1, Erkki Savilahti3, Willem M de Vos1, Mikko P Pakarinen2. 1. 1 Department of Bacteriology and Immunology, Immunobiology Research Program, University of Helsinki, Helsinki, Finland. 2. 2 Section of Pediatric Surgery, Pediatric Liver and Gut Research Group, Children's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland. 3. 3 Division of Pediatric Gastroenterology, Children's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
Abstract
BACKGROUND: Intestinal failure (IF)-associated liver disease (IFALD) is the major cause of mortality in IF. The link between intestinal microbiota and IFALD is unclear. METHODS: We compared intestinal microbiota of patients with IF (n = 23) with healthy controls (n = 58) using culture-independent phylogenetic microarray analysis. The microbiota was related to histological liver injury, fecal markers of intestinal inflammation, matrix metalloproteinase 9 and calprotectin, and disease characteristics. RESULTS: Overabundance of Lactobacilli, Proteobacteria, and Actinobacteria was observed in IF, whereas bacteria related to Clostridium clusters III, IV, and XIVa along with overall diversity and richness were reduced. Patients were segregated into 3 subgroups based on dominating bacteria: Clostridium cluster XIVa, Proteobacteria, and bacteria related to Lactobacillus plantarum. In addition to liver steatosis and fibrosis, Proteobacteria were associated with prolonged current parenteral nutrition (PN) as well as liver and intestinal inflammation. Lactobacilli were related to advanced steatosis and fibrosis mostly after weaning off PN without associated inflammation. In multivariate permutational analysis of variance, liver steatosis, bowel length, PN calories, and antibiotic treatment best explained the microbiota variation among patients with IF. CONCLUSIONS: Intestinal microbiota composition was associated with liver steatosis in IF and better predicted steatosis than duration of PN or length of the remaining intestine. Our results may be explained by a model in which steatosis is initiated during PN in response to proinflammatory lipopolysaccharides produced by Proteobacteria and progresses after weaning off PN, as the L plantarum group Lactobacilli becomes dominant and affects lipid metabolism by altering bile acid signaling.
BACKGROUND:Intestinal failure (IF)-associated liver disease (IFALD) is the major cause of mortality in IF. The link between intestinal microbiota and IFALD is unclear. METHODS: We compared intestinal microbiota of patients with IF (n = 23) with healthy controls (n = 58) using culture-independent phylogenetic microarray analysis. The microbiota was related to histological liver injury, fecal markers of intestinal inflammation, matrix metalloproteinase 9 and calprotectin, and disease characteristics. RESULTS: Overabundance of Lactobacilli, Proteobacteria, and Actinobacteria was observed in IF, whereas bacteria related to Clostridium clusters III, IV, and XIVa along with overall diversity and richness were reduced. Patients were segregated into 3 subgroups based on dominating bacteria: Clostridium cluster XIVa, Proteobacteria, and bacteria related to Lactobacillus plantarum. In addition to liver steatosis and fibrosis, Proteobacteria were associated with prolonged current parenteral nutrition (PN) as well as liver and intestinal inflammation. Lactobacilli were related to advanced steatosis and fibrosis mostly after weaning off PN without associated inflammation. In multivariate permutational analysis of variance, liver steatosis, bowel length, PN calories, and antibiotic treatment best explained the microbiota variation among patients with IF. CONCLUSIONS: Intestinal microbiota composition was associated with liver steatosis in IF and better predicted steatosis than duration of PN or length of the remaining intestine. Our results may be explained by a model in which steatosis is initiated during PN in response to proinflammatory lipopolysaccharides produced by Proteobacteria and progresses after weaning off PN, as the L plantarum group Lactobacilli becomes dominant and affects lipid metabolism by altering bile acid signaling.
Entities:
Keywords:
Lactobacilli; Proteobacteria; liver disease; parenteral nutrition; short bowel syndrome
Authors: Lauren K Barron; Christopher P Gayer; Anne Roberts; Jamie M Golden; Bola G Aladegbami; Jun Guo; Christopher R Erwin; Brad W Warner Journal: Surgery Date: 2016-08-31 Impact factor: 3.982
Authors: Lauren K Barron; James W Bao; Bola G Aladegbami; Jason J Colasanti; Jun Guo; Christopher R Erwin; Brad W Warner Journal: J Pediatr Surg Date: 2017-03-16 Impact factor: 2.545
Authors: Emily J Onufer; Rafael Czepielewski; Kristen M Seiler; Emma Erlich; Cathleen M Courtney; Aiza Bustos; Gwendalyn J Randolph; Brad W Warner Journal: J Pediatr Surg Date: 2019-02-28 Impact factor: 2.545
Authors: Harold J Boutte; Jacqueline Chen; Todd N Wylie; Kristine M Wylie; Yan Xie; Mackenzie Geisman; Anirudh Prabu; Vered Gazit; Phillip I Tarr; Marc S Levin; Brad W Warner; Nicholas O Davidson; Deborah C Rubin Journal: Am J Physiol Gastrointest Liver Physiol Date: 2021-11-24 Impact factor: 4.052
Authors: Holly J Engelstad; Lauren Barron; Joseph Moen; Todd N Wylie; Kristine Wylie; Deborah C Rubin; Nicholas Davidson; W Todd Cade; Barbara B Warner; Brad W Warner Journal: J Am Coll Surg Date: 2018-08-02 Impact factor: 6.113
Authors: Cathleen M Courtney; Emily J Onufer; Keely G McDonald; Allie E Steinberger; Anne M Sescleifer; Kristen M Seiler; Maria E Tecos; Rodney D Newberry; Brad W Warner Journal: J Surg Res Date: 2020-09-28 Impact factor: 2.192